Study Evaluating Prevenar in High-Risk Children
Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Listed as NCT00234338, this observational or N/A phase trial focuses on Pneumococcal Disease and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .